Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy

PURPOSE: Cutaneous squamous cell carcinoma (CSCC) is a common cancer that in most cases is curable with surgery. About 3–5% of patients develop advanced CSCC (aCSCC) and are no longer responsive to surgery or radiation therapy. The aim of this study was to assess the cost-effectiveness and cost-util...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghetti, Gianni, D’Avella, Maria Claudia, Pradelli, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882423/
https://www.ncbi.nlm.nih.gov/pubmed/33603419
http://dx.doi.org/10.2147/CEOR.S295605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882423/
https://www.ncbi.nlm.nih.gov/pubmed/33603419
http://dx.doi.org/10.2147/CEOR.S295605

Ejemplares similares